P-Coumaric Acid

Pharmacology & Research

p-Coumaric acid (4-hydroxycinnamic acid) is a simple hydroxycinnamic acid — the mono-hydroxylated member of the cinnamic-acid phenolic family, one methylation and one hydroxylation removed from its relatives caffeic acid and ferulic acid. It is one of the most widely distributed phenolic acids in the plant kingdom: it turns up in nearly every herb in this database — fennel, marshmallow, yerba maté, samambaia, couchgrass, chelidonium and blue lotus among them — usually as a minor free-acid fraction on top of much larger amounts bound to cell-wall polysaccharides or esterified into larger molecules. It is also endogenous, formed from the amino acids tyrosine and phenylalanine, so it is not a foreign xenobiotic. The evidence posture is lopsided: it has a genuinely strong, human-validated story in skin (a potent, selective tyrosinase inhibitor delivered topically), and a broad but almost entirely preclinical spread of antioxidant, antiplatelet, antidiabetic and antimicrobial signals. The reason that matters is pharmacokinetic — p-coumaric acid is absorbed intact and comparatively well for a phenolic acid, but it is then rapidly conjugated to glucuronides and sulfates ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}, so the free molecule tested in vitro is largely not the species circulating in the body.

1. Skin & photoprotection

The strongest line, and the only one with human data on the isolate. Isolated p-coumaric acid has a structure that mimics L-tyrosine, letting it act as a competitive inhibitor of human tyrosinase — the rate-limiting enzyme of melanin synthesis — and it inhibited melanogenesis in human melanocytes and reconstructed skin, reportedly more potently against the human enzyme than arbutin or kojic acid ^{2Reference 2Boo YC · 2019Reviewp-Coumaric Acid as an Active Ingredient in Cosmetics: A Review Focusing on Its Antimelanogenic Effects — reviewView study →3Reference 3An SM et al. · 2010In vitrop-Coumaric acid not only inhibits human tyrosinase activity in vitro but also melanogenesis in cells exposed to UVB — in vitro / human melanocytesView study →}. In a small controlled human study, a topical p-coumaric acid cream applied to the forearm markedly reduced UV-induced erythema and, with continued use, skin pigmentation ^{4Reference 4Seo YK et al. · 2011Clinical trialEffects of p-coumaric acid on erythema and pigmentation of human skin exposed to ultraviolet radiation — small human study (topical)View study →}. The cinnamate chromophore also absorbs UV directly, adding a photoprotective mechanism on top of antioxidant quenching ^{2Reference 2Boo YC · 2019Reviewp-Coumaric Acid as an Active Ingredient in Cosmetics: A Review Focusing on Its Antimelanogenic Effects — reviewView study →}.

Gap: the human evidence is a single small topical study ^{4Reference 4Seo YK et al. · 2011Clinical trialEffects of p-coumaric acid on erythema and pigmentation of human skin exposed to ultraviolet radiation — small human study (topical)View study →}; there is no large trial, and the systemic (oral) route is undercut by conjugation, so this signal is essentially a topical one.

2. Antioxidant (property)

The foundational activity. As the isolated molecule, p-coumaric acid scavenges DPPH, peroxyl and other radicals and lowers lipid peroxidation; it was among the antioxidant phenolics identified in and contributing to the activity of the samambaia (Polypodium leucotomos) extract ^{11Reference 11Gombau L et al. · 2006In vitroPolypodium leucotomos extract: antioxidant activity and disposition — in vitro (samambaia; p-coumaric acid among the phenolics)View study →} and was one of the active radical-scavengers isolated from blue lotus flowers ^{14Reference 14Agnihotri VK et al. · 2008In vitroAntioxidant constituents of Nymphaea caerulea flowers — isolation / in vitro (blue lotus)View study →}. Mono-phenol chemistry makes it a somewhat weaker direct scavenger than the catechol-bearing caffeic acid, but it is still a competent hydrogen/electron donor ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}.

Gap: most assays are cell-free or in-vitro on the free acid; in the body p-coumaric acid is rapidly conjugated (see Pharmacokinetics), so the circulating antioxidant is largely its glucuronide/sulfate conjugates, whose activity differs from the parent ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}.

3. Antiplatelet / cardiovascular

Isolated p-coumaric acid inhibits platelet activity. In human platelets in vitro (500 µM–1 mM) and in rabbits fed 5 mg/kg for two weeks it reduced ADP-induced aggregation without affecting coagulation, an effect tied to lower thromboxane B2 production, reduced P-selectin expression and raised platelet cAMP, alongside increased plasma antioxidant capacity ^{5Reference 5Luceri C et al. · 2007In vitrop-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo — in vitro human platelets + rabbit in vivoView study →}. It also appears among the phenolic acids credited with fennel’s vasoactive/antiplatelet fraction in cardiovascular reviews ^{16Reference 16Zahi A et al. · 2025ReviewCardiovascular effects, phytochemistry, drug interactions, and safety profile of Foeniculum vulgare (fennel): a comprehensive review — reviewView study →}, though that is whole-plant attribution.

Gap: the isolate data are in-vitro and a single rabbit study ^{5Reference 5Luceri C et al. · 2007In vitrop-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo — in vitro human platelets + rabbit in vivoView study →}; no human cardiovascular endpoint, and the in-vitro concentrations are far above physiological free-acid plasma levels.

4. Antidiabetic / metabolic

Isolated p-coumaric acid improves glycaemic markers in rodents. In streptozotocin-diabetic rats it lowered blood glucose and gluconeogenic enzymes (glucose-6-phosphatase, fructose-1,6-bisphosphatase) while raising hexokinase and pancreatic GLUT2 expression, framed as protection of β-cell function ^{6Reference 6Amalan V et al. · 2016AnimalAntidiabetic and antihyperlipidemic activity of p-coumaric acid in diabetic rats, role of pancreatic GLUT 2: in vivo approach — rat modelView study →}; in high-fat-diet diabetic rats, 20 mg/kg for 12 weeks reduced hyperglycaemia and attenuated oxidative kidney damage (diabetic nephropathy) ^{7Reference 7Mani A et al. · 2022Animalp-Coumaric acid attenuates high-fat diet-induced oxidative stress and nephropathy in diabetic rats — rat modelView study →}.

Gap: entirely rodent, with mechanisms that overlap heavily with the generic antioxidant action; no human metabolic data and no dose bridging to people ^{6Reference 6Amalan V et al. · 2016AnimalAntidiabetic and antihyperlipidemic activity of p-coumaric acid in diabetic rats, role of pancreatic GLUT 2: in vivo approach — rat modelView study →7Reference 7Mani A et al. · 2022Animalp-Coumaric acid attenuates high-fat diet-induced oxidative stress and nephropathy in diabetic rats — rat modelView study →}.

5. Antimicrobial

As the isolated molecule, p-coumaric acid kills bacteria through a dual mechanism — permeabilising the outer and plasma membranes (loss of barrier function, ATP leakage, membrane hyperpolarisation) and binding/intercalating bacterial genomic DNA to disrupt replication and transcription ^{10Reference 10Lou Z et al. · 2012In vitrop-Coumaric acid kills bacteria through dual damage mechanisms — in vitro mechanisticView study →}. At the whole-plant level it is among the phenolic acids credited with the antibacterial activity of yerba maté extracts against S. aureus, Listeria and Salmonella ^{13Reference 13Prado Martin JG et al. · 2013In vitroAntimicrobial activity of yerba maté (Ilex paraguariensis) against food pathogens — in vitro (whole-extract)View study →}, and its lipophilic C16 ester (hexadecyl-coumaric-acid ester) is the anti-adhesion agent isolated from couchgrass rhizome against uropathogenic E. coli — though that ester is poorly water-extracted and is a different molecule from the free acid ^{12Reference 12Beydokhti SS et al. · 2017In vitroHexadecyl coumaric acid ester from the rhizomes of Agropyron repens with antiadhesive activity against uropathogenic E. coli — in vitro (couchgrass)View study →}. Attribution should stay honest, though: in an antibiofilm screen of chelidonium and other Papaveraceae, activity tracked quercetin, and no correlation was found for the co-occurring p-coumaric acid ^{15Reference 15Zielińska S et al. · 2021In vitroScreening Papaveraceae as novel antibiofilm natural-based agents — in vitro (chelidonium; p-coumaric acid detected)View study →}.

Gap: the mechanistic work is in-vitro at high concentrations ^{10Reference 10Lou Z et al. · 2012In vitrop-Coumaric acid kills bacteria through dual damage mechanisms — in vitro mechanisticView study →}; the herb-level activity is extract- or ester-based, not clean isolate efficacy, and there is no in-vivo infection model for the free acid.

Mechanisms

Target / pathway	Effect	Relevant to
Direct radical / ROS quenching (phenol + cinnamate)	scavenges DPPH/peroxyl, ↓lipid peroxidation	antioxidant
Tyrosinase (competitive, L-tyrosine mimic)	inhibits → ↓melanin synthesis	skin depigmentation
UV absorption (cinnamate chromophore)	absorbs UVB → ↓erythema / photodamage	photoprotection
Thromboxane B2 / P-selectin / platelet cAMP	↓TXB2, ↓P-selectin, ↑cAMP → ↓aggregation	antiplatelet / cardiovascular
Pancreatic GLUT2 + gluconeogenic enzymes	↑hexokinase, ↓glucose-6-phosphatase, ↑insulin	antidiabetic
Bacterial membrane + genomic DNA	permeabilisation + DNA intercalation	antimicrobial

Pharmacokinetics

Bioavailability is the load-bearing caveat, and here it cuts two ways. Unusually for a phenolic acid, p-coumaric acid is absorbed rapidly and comparatively well as the intact molecule: in rats an oral dose appeared in serum within ~10 minutes and reached a Cmax around 166 µmol/L, with roughly 70-fold higher relative bioavailability than gallic acid ^{8Reference 8Konishi Y et al. · 2004AnimalIntestinal absorption of p-coumaric and gallic acids in rats after oral administration — rat pharmacokineticsView study →}, and Caco-2 work shows it crosses the intestinal epithelium via the monocarboxylic acid transporter (MCT) in a pH-dependent, saturable fashion rather than by passive diffusion ^{9Reference 9Konishi Y et al. · 2003In vitroTransepithelial transport of p-coumaric acid and gallic acid in Caco-2 cell monolayers — in vitro intestinal transportView study →}. The catch is what happens next: absorbed p-coumaric acid undergoes rapid, extensive phase-II conjugation — glucuronidation (UGT) and sulfation (SULT) to species such as p-coumaric acid-4′-glucuronide and 4′-sulfate — so systemic exposure to the free acid is small and short-lived, and human bioavailability of the parent is estimated at roughly 25% ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}. Much of dietary p-coumaric acid is also bound (esterified to cell-wall polysaccharides or glycosylated), and gut microbiota liberate it before absorption and further degrade it to smaller phenolics ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}. Two practical consequences follow: (1) the free-acid potency measured in antioxidant and enzyme assays is not the species mainly circulating in blood — the conjugates are, and their activity differs from the parent ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}; and (2) this is precisely why the topical skin data are the strongest — a cream on the skin bypasses the conjugation that blunts oral dosing ^{4Reference 4Seo YK et al. · 2011Clinical trialEffects of p-coumaric acid on erythema and pigmentation of human skin exposed to ultraviolet radiation — small human study (topical)View study →}.

Clinical trials

The only human trial of isolated p-coumaric acid is topical — a small controlled study of a p-coumaric acid cream for UV-induced erythema and pigmentation ^{4Reference 4Seo YK et al. · 2011Clinical trialEffects of p-coumaric acid on erythema and pigmentation of human skin exposed to ultraviolet radiation — small human study (topical)View study →}. There is no human RCT of orally-dosed isolated p-coumaric acid for any systemic indication; the rest of the human literature is whole-food and whole-plant intake, which is a mixed-phenolic exposure and cannot be read as a molecule result.

Last checked: July 2026.

Toxicity & Safety

p-Coumaric acid carries a low toxicity flag. It is one of the most common phenolic acids in the human diet — present in most fruits, grains, vegetables and beverages — and is additionally made endogenously from tyrosine, so ordinary dietary and herbal exposure has no described acute toxicity or overdose syndrome, and reviews describe it as generally well tolerated in animal studies at the doses used ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}. Notably, and unlike its relative caffeic acid, it does not carry a high-dose rodent forestomach-carcinogenicity signal; if anything the isolate is reported as antimutagenic and a nitrosation inhibitor ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →}. The small topical human study reported it was well tolerated on skin over weeks of use ^{4Reference 4Seo YK et al. · 2011Clinical trialEffects of p-coumaric acid on erythema and pigmentation of human skin exposed to ultraviolet radiation — small human study (topical)View study →}.

The realistic cautions are theoretical and mechanism-based rather than documented clinical events. Its antiplatelet action ^{5Reference 5Luceri C et al. · 2007In vitrop-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo — in vitro human platelets + rabbit in vivoView study →} is an additive concern in principle with antiplatelet or anticoagulant drugs, though no clinical interaction has been reported. As a substrate for UGT/SULT conjugation and for the monocarboxylic acid transporter ^{1Reference 1Pei K et al. · 2016Reviewp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities — reviewView study →9Reference 9Konishi Y et al. · 2003In vitroTransepithelial transport of p-coumaric acid and gallic acid in Caco-2 cell monolayers — in vitro intestinal transportView study →}, it could in theory compete with other heavily-conjugated or MCT-transported compounds, but this is unquantified in people. No well-characterised human drug interactions exist for the isolate, and formal interaction, reproductive and long-term safety datasets for isolated p-coumaric acid have not been established — absence of a signal here reflects absence of testing, not proven safety.

Dosage

There is no established human dose for isolated p-coumaric acid, and nothing here is a recommendation. The only human dosing on record is topical — a p-coumaric acid cream applied to skin before and after UV exposure ^{4Reference 4Seo YK et al. · 2011Clinical trialEffects of p-coumaric acid on erythema and pigmentation of human skin exposed to ultraviolet radiation — small human study (topical)View study →}, which does not generalise to oral use. For scale only, preclinical work used oral doses around 20 mg/kg/day in rats over weeks for the antidiabetic and nephropathy endpoints ^{6Reference 6Amalan V et al. · 2016AnimalAntidiabetic and antihyperlipidemic activity of p-coumaric acid in diabetic rats, role of pancreatic GLUT 2: in vivo approach — rat modelView study →7Reference 7Mani A et al. · 2022Animalp-Coumaric acid attenuates high-fat diet-induced oxidative stress and nephropathy in diabetic rats — rat modelView study →}, 5 mg/kg in rabbits for the antiplatelet effect ^{5Reference 5Luceri C et al. · 2007In vitrop-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo — in vitro human platelets + rabbit in vivoView study →}, and high-micromolar to low-millimolar concentrations in cell and biochemical assays ^{5Reference 5Luceri C et al. · 2007In vitrop-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo — in vitro human platelets + rabbit in vivoView study →10Reference 10Lou Z et al. · 2012In vitrop-Coumaric acid kills bacteria through dual damage mechanisms — in vitro mechanisticView study →} — figures that the rapid conjugation of the free acid (see Pharmacokinetics) makes hard to reach systemically from an oral dose. In practice p-coumaric acid is obtained through diet and whole herbs; there is no evidence base supporting isolated high-dose oral supplementation. These are doses studied in research and are not a personal recommendation.

References